Treatment of tuberculosis according to the different pattern of resistance;Tratamiento de la tuberculosis según el diferente patrón de resistencias

Medicina Clinica

Volumn 134, Issue 4, 2010, Pages 173-181

  Caminero, José A ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

MDR; Mutidrug resistance; Tuberculosis; XDR

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; POLYPEPTIDE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; THIAMINE;

ANTIBIOTIC SENSITIVITY; DEPRESSION; EOSINOPHILIC ENTERITIS; FACIAL NERVE DISEASE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; LEUKOPENIA; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEURITIS; OPTIC NEURITIS; OTOTOXICITY; PERSONALITY DISORDER; PIGMENT DISORDER; PROGNOSIS; REVIEW; TENOSYNOVITIS; TUBERCULOSIS;

EID: 76149136369     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.12.024     Document Type: Short Survey

References (71)

1. J.A. Caminero Luna Guía de la tuberculosis para médicos especialistas. International Union Against Tuberculosis and Lung Disease, editor 2003 Imprimerie Chirat Paris
2. J. Lehmann Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials [editorial] Am Rev Respir Dis 90 1964 953 956
3. J.A. Caminero Treatment of multidrug-resistant tuberculosis: evidence and controversies Int J Tuberc Lung Dis 10 2006 829 837 (Pubitemid 44197841)
4. M. Zignol, M.S. Hosseini, A. Wright, C. Lambregts-van Weezenbeek, P. Nunn, and C.J. Watt Global incidence of multidrug-resistant tuberculosis J Infect Dis 194 2006 479 485 (Pubitemid 44162659)
5. o 4. World Health Organization Document, WHO/HTM/TB. 2008.394:1-120.
6. World Health Organization. Guidelines of the programmatic management of drug-resistant tuberculosis. World Health Organization Document, 2006. WHO/HTM/TB. 2006.361:1-174.
7. World Health Organization. The global MDR-TB & XDR-TB response plan 2007-2008. World Health Organization Document, 2007. WHO/HTM/STB. 2007;387:1-51.
8. M.C. Raviglione, and I.M. Smith XDR tuberculosis - implications for global public health N Engl J Med 356 2007 656 659 (Pubitemid 46257227)
9. British Medical Research Council Streptomycin treatment of pulmonary tuberculosis. A medical research council investigation BMJ 2 1948 769 783
10. E.R. Long, and S.H. Ferebee A controlled investigation of streptomycin treatment in pulmonary tuberculosis Public Health Rep 65 1950 1421 1451
11. J.A. Caminero Luna Origen, presente y futuro de las resistencias en tuberculosis Arch Bronconeumol 37 2001 35 42
12. British Medical Research Council Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. A Medical Research Council investigation BMJ 2 1950 1073 1085
13. J. Crofton «Sputum conversion» and the metabolism of isoniazid [correspondence] Am Rev Tuberc Pulm Dis 77 1958 869 871
14. B. Doster, F.J. Murray, R. Newman, and S.F. Woolpert Ethambutol in the initial treatment of pulmonary tuberculosis Am Rev Respir Dis 107 1973 177 190
15. J.A. Caminero Luna A tuberculosis guide for specialist physicians. International Union Against Tuberculosis and Lung Disease, editor 2004 Imprimerie Chirat Paris
16. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, and R.E. Chaisson Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med 169 2004 421 426 (Pubitemid 38134824)
17. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis [revision]. Cochrane Database of Systematic Reviews. 2008:1:CD004795, doi:10.1002/14651858.CD004795.pub3.008.
18. R. Newman, B. Doster, F.J. Murray, and S. Ferebee Rifampin in initial treatment of pulmonary tuberculosis. A US Public Health Service tuberculosis therapy trial Am Rev Respir Dis 103 1971 461 476
19. G. Brouet, and G. Roussel Essai 6.9.12. Méthodologie globale et synthèse des résultats Rev Fr Mal Respir 5 Suppl 1 1977 5 13 (Pubitemid 8373782)
20. W. Fox Whither short-course chemotherapy? Br J Dis Chest 75 1981 331 357 (Pubitemid 11018322)
21. W. Fox, G.A. Ellard, and D.A. Mitchison Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications Int J Tuberc Lung Dis 3 Suppl 2 1999 S231 S279 (Pubitemid 29481843)
22. World Health Organization Treatment of tuberculosis: guidelines for national programmes 3rd ed 2003 World Health Organization Document WHO/CDS/TB. 2003.313:1-108
23. S.J. Kim, M.A. Espinal, C. Abe, G.H. Bai, F. Boulahbal, and L. Fattorini Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 8 2004 1157 1158 (Pubitemid 39201267)
24. J.A. Caminero Luna Resistencia primaria a fármacos antituberculosos Med Clin (Barc) 93 1989 30 36
25. J.A. Caminero Management of multidrug-resistant tuberculosis and patients in retreatment Eur Respir J 25 2005 928 936 (Pubitemid 40667694)
26. S.J. Kim Drug-susceptibility testing in tuberculosis: methods and reliability of results Eur Respir J 25 2005 564 569
27. World Health Organization Global tuberculosis control: surveillance, planning, financing. WHO Report 2007 2007 World Health Organization Document WHO/HTM/TB. 2007;376:1-270
28. A. Marrero, J.A. Caminero, and N.E. Billo Towards elimination of tuberculosis in a low income country: the experience of Cuba, 1962-1997 Thorax 55 2000 39 45 (Pubitemid 30248777)
29. East African/British Medical Research Council Controlled clinical trial of four short-course (6-month) regimens of chemothearpy for treatment of pulmonary tuberculosis Lancet 2 1974 1100 1106
30. J.A. Caminero, J.M. Pavón, F. Rodríguez de Castro, F. Díaz, G. Julià, J.A. Caylà, et al. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance Thorax 51 1996 1130 1133
31. A. Vernon, W. Burman, D. Benator, A. Khan, and L. Bozeman Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid Lancet 353 1999 1843 1847 (Pubitemid 29251017)
32. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America Treatment of tuberculosis Am J Respir Crit Care Med 167 2003 603 662
33. D.A. Mitchison Role of individual drugs in the chemotherapy of tuberculosis Int J Tuberc Lung Dis 4 2000 796 806
34. J.A. Caminero Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation Int J Tuberc Lung Dis 128 2008 68 77
35. M.A. Espinal, S.J. Kim, P.G. Suarez, K.M. Kam, A.G. Khomenko, G.B. Migliori, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries JAMA 283 2000 2537 2545
36. C.Y. Chiang, D.A. Enarson, M.C. Yu, K.J. Bai, R.M. Huang, C.J. Hsu, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Eur Respir J 28 2006 980 985
37. M. Narita, P. Alonso, M. Lauzardo, E.S. Hollender, A.E. Pitchenik, and D. Ashkin Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997 Chest 120 2001 343 348 (Pubitemid 32881245)
38. W.A. Geerligs, R. Van Altena, W.C.M. De Lange, D. Van Soolingen, and T.S. Van der Werf Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands Int J Tuberc Lung Dis 4 2000 758 764 (Pubitemid 30650034)
39. M. Burgos, L.C. Gonzalez, E.A. Paz, E. Gournis, L.M. Kawamura, and G. Schecter Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach Clin Infect Dis 40 2005 968 975 (Pubitemid 40418303)
40. M. Goble, M.D. Iseman, L.A. Madsen, D. Waite, L. Ackerson, and C.R. Horsburgh Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin N Engl J Med 328 1993 527 532 (Pubitemid 23053828)
41. P.G. Suárez, K. Floyd, J. Portocarrero, E. Alarcón, E. Rapiti, and G. Ramos Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru Lancet 359 2002 1980 1989 (Pubitemid 34663712)
42. G.B. Migliori, G. Besozzi, E. Girardi, K. Kliiman, C. Lange, O.S. Toungoussova, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition Eur Respir J 30 2007 623 626
43. C. Mitnick, J. Bayona, E. Palacios, S. Shin, J. Furin, and F. Alcántara Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru N Engl J Med 348 2003 119 128 (Pubitemid 36056718)
44. E.D. Chan, V. Laurel, M.J. Strand, J.F. Chan, M.L.N. Huynh, and M. Goble Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis Am J Respir Crit Care Med 169 2004 1103 1109 (Pubitemid 38624789)
45. G.B. Migliori, C. Lange, E. Girardi, R. Centis, G. Besozzi, K. Kliiman, et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results Clin Infect Dis 46 2008 958 959
46. D.J. Palmero, M. Ambroggi, A. Brea, M. De Lucas, A. Fulgenzi, and D. Martínez Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina Int J Tuberc Lung Dis 8 2004 778 784 (Pubitemid 38747156)
47. V. Leimane, V. Riekstina, T.H. Holtz, E. Zarovska, V. Skripconoka, and L.E. Thorpe Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study Lancet 365 2005 318 326 (Pubitemid 40139109)
48. E. Nathanson, C. Lambregts van Weezenbeek, M.L. Rich, R. Gupta, J. Bayona, K. Blöndal, et al. Multidrug-resistant tuberculosis management in resource-limited settings Emerg Infect Dis 12 2006 1389 1397
49. A. Van Deun, M.A. Hamid Salim, A.P. Kumar Das, I. Bastian, and F. Portaels Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh Int J Tuberc Lung Dis 8 2004 560 567 (Pubitemid 38656041)
50. D.A. Fischer, W. Lester, W.E. Dye, and T.S. Moulding Re-treatment of patients with isoniazid-resistant tuberculosis. Analysis and follow-up of 146 cases Am Rev Respir Dis 97 1968 392 398
51. I. Kass Chemotherapy regimens used in retreatment of pulmonary tuberculosis. Part I. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide Tubercle 46 1965 151 165
52. I. Kass Chemotherapy regimens used in retreatment of pulmonary tuberculosis. Part II. Observations on the efficacy of combinations of ethambutol, capreomycin and companion drugs, including 4-4 diisoamyloxythiosemicarbanilide Tubercle 46 1965 166 177
53. A. Pines Treatment of pulmonary tuberculosis with cultures resistant to two or more drugs: a series of 44 patients Tubercle 46 1965 131 142
54. J.F. Broekmans, G.B. Migliori, H.L. Rieder, J. Leese, P. Ruutu, R. Loddenkemper Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group European framework for tuberculosis control and elimination in countries with a low incidence Eur Respir J 19 2002 765 775 (Pubitemid 34285174)
55. S. Grzybowski, and D.A. Enarson The fate of cases of pulmonary tuberculosis under various treatment programmes Bull Int Union Tuberc Lung Dis 53 1978 70 75 (Pubitemid 9240283)
56. J.A. Caminero Extensively drug-resistant tuberculosis: is its definition correct? Eur Respir J 32 2008 1413 1415
57. N.R. Gandhi, A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa Lancet 368 2006 1575 1580
58. Centers for Disease Control and Prevention Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004 Morb Mortal Wkly Rep 55 2006 301 305
59. C.Y. Jeon Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcome among patients at a tertiary referral hospital Clin Infect Dis 46 2008 42 49
60. A. Krüüner, P. Jureen, K. Levina, S. Ghebremichael, and S. Hoffner Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 2971 2973 (Pubitemid 37040278)
61. M. Tsukamura, and S. Mizuno Studies on the cross-resistance of Mycobacterium tuberculosis, strain H37Rv, to aminoglycoside- and polypeptide-antibiotics Microbiol Immunol 24 1980 777 787 (Pubitemid 11215534)
62. J.G. Somocurcio, A. Sotomayor, S. Shin, S. Portilla, M. Valcarcel, and D. Guerra Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru Thorax 62 2007 416 421 (Pubitemid 46698391)
63. C.D. Mitnick, S.S. Shin, K.J. Seung, M.L. Rich, S. Atwood, J.J. Furin, et al. Comprehensive treatment of extensively drug-resistant tuberculosis N Engl J Med 359 2008 563 574
64. J. Tousek, E. Jancik, M. Zelenka, and M. Jancikova-Máková The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up Tubercle 48 1967 27 31
65. M. Zierski, and A. Zachara Late results in re-treatment of patients with pulmonary tuberculosis Tubercle 51 1970 172 177
66. A.R. Somner, and A.A. Brace Late results of treatment of chronic drug-resistant pulmonary tuberculosis BMJ 1 1966 775 778
67. I. Kass Chemotherapy regimens used in retreatment of pulmonary tuberculosis. Part I. Observations on the efficacy of combinations of kanamycin, ethinamide and either cycloserine or pyrazinamide Tubercle 46 1965 151 165
68. K.M. Kam, C.W. Yip, T.L. Cheung, H.S. Tang, O.C. Leung, and M.Y. Chan Stepwise decrease in moxifloxacin susceptibility amongs clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility Microb Drug Resistance 12 2006 7 11
69. G.J. Alangaden, B.N. Kreiswirth, A. Aouad, M. Khetarpal, F.R. Igno, and S.L. Moghazeh Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis Antimicrob Agents Chemother 42 1998 1295 1297 (Pubitemid 28227943)
70. M. Tsukamura Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubercle bacilli from patients Am Rev Respir Dis 99 1969 780 782
71. S.K. Katiyar, S. Bihari, S. Prakash, M. Mamtani, and H. Kulkarni A randomised controlled trial of hihg-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 12 2008 129 145